The BioInsights Podcast

BioInsights
  • 5.0 (4)
  • LIFE SCIENCES

The BioInsights Podcast: discussing the challenges of translating novel biologics from bench to clinic to market.

  1. 6D AGO

    Crossing the ADC inflection points: what separates clinical success from failure

    Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Antoine Yver, Board Chair, Ona Therapeutics, with more than three and a half decades of experience shaping global cancer drug development. In this conversation, they explore what determines whether an ADC successfully crosses the critical threshold and how teams should rethink dose finding, toxicity, and what it truly takes to set a program up for long-term success in the clinic.

    30 min

  2. 11/06/2025

    Formulation and delivery of RNA-based vaccines and therapeutics: addressing outstanding questions around safety and purity

    In this interview, Róisin McGuigan, Editor, Nucleic Acid Insights, and Jesse Erasmus, Director of Virology at HDT Bio, discuss current challenges and opportunities in RNA safety, manufacturing, and targeted delivery, and the key ongoing obstacles facing viral and LNP-based delivery modalities.

    24 min

  3. 10/27/2025

    Advancing nucleic acid therapeutics with circular RNA

    In this podcast episode, Jokūbas Leikauskas, Editor, BioInsights, speaks to Trevor Hallam, who served as Chief Scientific Officer of Sail Biomedicines until July 2025. The interview, recorded in June 2025, explores advances in RNA therapeutics, particularly circular RNA (circRNA or eRNA) technologies, and how they may help overcome current limitations in delivery, durability, and specificity for applications such as CAR-T cell therapies and autoimmune disease treatment.

    34 min

  4. 10/01/2025

    Exploring advances in bioconjugation: nanozymes, tissue tropism, and the future of responsive systems

    Lauren Coyle (Commissioning Editor, Bioconjugation Insights) speaks to Vincent Rotello (Distinguished Professor of Chemistry, University of Massachusetts Amherst) about the advantages and limitations of different nanomaterial platforms, and emerging strategies such as tissue tropism and responsive nanozymes that could advance targeted therapeutic and diagnostic delivery.

    15 min

  5. 08/27/2025

    The promise of antibody-oligonucleotide conjugates for neurological diseases

    Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, speaks with Kerstin Hofer, Science and People Lead, Roche, about the evolving application of antibody-oligonucleotide conjugates in neurology. She highlights their design, delivery challenges across the blood–brain barrier, and potential to transform CNS diseases.

    21 min

  6. 07/18/2025

    From innovation to access: bridging gaps in scalability and cold chain precision logistics for advanced therapies

    Jokūbas Leikauskas, Editor, BioInsights, speaks to Rohin Iyer, Senior Director, Global Cell and Gene Therapy Operations, Marken, about addressing the complex logistics of cell and gene therapies through global infrastructure, precision, and advanced technologies. They also discuss evolving cold chain needs, regulatory and geopolitical challenges, and the need for scalability.

    20 min

  7. 03/27/2025

    Enhancing mRNA results through strategic RNA design and quality control

    In the last few years, mRNA has moved to the fore in the vaccine and cell and gene therapy fields, and as a result, its successful production for these downstream applications has never been more crucial. In this podcast episode, Róisin McGuigan, Editor, Nucleic Acid Insights, speaks to Ryan Lahr, Senior R&D Scientist, CELLSCRIPT, about design, production, and quality control of synthesized mRNA for translation in cells.

    13 min

  8. 03/13/2025

    For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications

    Roisin McGuigan, Commissioning Editor, Nucleic Acid Insights, speaks to Stanley Crooke, Chairman, Founder and CEO, n-Lorem, about his long career and pioneering role in the antisense oligonucleotide (ASO) space, how RNA-targeting therapies are set to enter the mainstream, and his latest focus: making personalized, free-for-life ASO therapies available to nano-rare patient populations.

    19 min
See All (59)

Ratings & Reviews

5
out of 5
4 Ratings

About

The BioInsights Podcast: discussing the challenges of translating novel biologics from bench to clinic to market.

Information

  • Creator
    BioInsights
  • Years Active
    2022 - 2026
  • Episodes
    59
  • Rating
    Clean
  • Copyright
    © 2026 The BioInsights Podcast
  • Show Website
    The BioInsights Podcast